SBIR-STTR Award

Protein-Modified Hydrogels For Expansion Of Human Embryonic Stem Cells
Award last edited on: 6/29/10

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$131,371
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Terry Tandeski

Company Information

Glycosan BioSystems Inc

1301 Harbor Bay Parkway
Alameda, CA 94502
   (877) 636-4978
   N/A
   www.glycosan.com
Location: Single
Congr. District: 13
County: Alameda

Phase I

Contract Number: 1R43GM087765-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2009
Phase I Amount
$131,371
The realization of the remarkable potential of human embryonic stem cells or induced pluripotent stem cells to treat human disease cannot occur unless new animal-free methods for the expansion of undifferentiated stem cells are developed. An optimal extracellular matrix (ECM) substitute for the expansion of human embryonic stem cells (hESCs) in three dimensions (3-D) would be a soft hydrogel that includes two key features. First, the hydrogel should be composed of animal-free components to which researcher-provided ECM proteins or synthetic peptides can be covalently attached. Second, after multiple hESC divisions in an undifferentiated state, the hydrogel should allow rapid recovery of the expanded cell numbers without altering stemness. Glycosan BioSystems currently markets HyStem", an in situ-crosslinkable, semi-synthetic ECM composed of poly(ethylene glycol) diacrylate (PEGDA) and crosslinked thiol-modified hyaluronan ("Glycosil") for culture of a variety of pluripotent cell types. In Phase I we will test the feasibility of a simple system for attachment of proteins to the hydrogels that would covalently bind any selected human matricellular protein to the thiol-modified HA component of HyStem. This approach directly couples the "pull" of the cells on the proteins to the elastic modulus of the gel. In our first Aim, we would establish the optimal combination of covalently-linked human collagen, vitronectin, fibronectin, and laminin (CVFL) proteins, as well as the minimum amounts required, for effective self-renewal of H9 hESCs. Cells will be recovered and analyzed for stem cell markers by flow cytometry. Second, for each combination that gave suitable cell growth, we will employ a new reductively-cleavable linker to form soft gels that will allow enzyme-free recovery of undifferentiated hESCs from the gel surface. After cell recovery with 25 mM NAc-Cys, stemness will be assessed as before. Third, H9 hESCs will be encapsulated in 3D in selected HyStem-CVFL hydrogels, expanded in 3-D, and analyzed. Finally, we will use optimized conditions to expand stem cells for a minimum of 6 passages, and compare the karyotypes and stem cell markers with cells cultured on murine fibroblast feeders, on Matrigel, or on CVFL- coated plastic.

Public Health Relevance:
The realization of the remarkable potential of human embryonic stem cells or induced pluripotent stem cells to treat human disease cannot occur unless new animal-free methods for the expansion of undifferentiated stem cells are developed. Glycosan BioSystems currently markets HyStem", an in situ-crosslinkable, semi- synthetic ECM composed of poly(ethylene glycol) diacrylate (PEGDA) and crosslinked thiol-modified hyaluronan (Glycosil") for culture of a variety of pluripotent cell types. The goal of this proposal is to tailor HyStem for human embryonic stem cell culture by determining the optimal combination of covalently-bound attachment factors for proliferation without differentiation and by including a fall-apart crosslinker for gentle cell recovery.

Public Health Relevance Statement:
Project Narrative The realization of the remarkable potential of human embryonic stem cells or induced pluripotent stem cells to treat human disease cannot occur unless new animal-free methods for the expansion of undifferentiated stem cells are developed. Glycosan BioSystems currently markets HyStem", an in situ-crosslinkable, semi- synthetic ECM composed of poly(ethylene glycol) diacrylate (PEGDA) and crosslinked thiol-modified hyaluronan (Glycosil") for culture of a variety of pluripotent cell types. The goal of this proposal is to tailor HyStem for human embryonic stem cell culture by determining the optimal combination of covalently-bound attachment factors for proliferation without differentiation and by including a fall-apart crosslinker for gentle cell recovery.

NIH Spending Category:
Bioengineering; Regenerative Medicine; Stem Cell Research; Stem Cell Research - Embryonic - Human

Project Terms:
3-D; 3-Dimensional; Acetylcysteine; Acetylin; Airbron; Allen & Hanburys Brand of Acetylcysteine; Anaplastic; Animals; Basement membrane; Binding; Binding (Molecular Function); Binding Proteins; Blood Serum; Bristol-Myers Squibb Brand of Acetylcysteine; Bristol-Myers Squibb Brand of Acetylcysteine Sodium Salt; Broncholysin; Brunac; Cell Attachment; Cell Count; Cell Culture Techniques; Cell Number; Cell surface; Cell-Extracellular Matrix; Cell-Matrix Adhesions; Cell-Matrix Junction; Cells; Cellular Expansion; Cellular Growth; Clinical; Cold-Insoluble Globulins; Collagen; Collagen IV; Collagen Type IV; Complement S-Protein; Coupled; Couples; Crosslinker; Cysteine; Cytofluorometry, Flow; DNA analysis; Development; Dimensions; Disulfides; ECM; Encapsulated; Enzymes; Epibolin; Extracellular Matrix; Extracellular Matrix Proteins; FN1; FNZ; Fabrol; Fibroblasts; Fibronectin 1; Fibronectins; Flow Cytofluorometries; Flow Cytometry; Flow Microfluorimetry; Fluatox; Fluimucetin; Fluimucil; Fluprowit; Gel; Gelatin; Generalized Growth; Glycoprotein GP-2; Goals; Growth; Half-Cystine; Human; Human, General; Hyaluronan; Hyaluronic Acid; Hydrogels; In Situ; Inpharzam Brand of Acetylcysteine; Investigators; L-Alpha-acetamido-beta-mercaptopropionic Acid; L-Cysteine; LETS Proteins; LKE antigen; Laminin; Large External Transformation-Sensitive Protein; Ligand Binding Protein; Link; Macrogols; Maleimides; Mammals, Mice; Man (Taxonomy); Man, Modern; Marketing; Mercaptans; Mercapto Compounds; Mercapturic Acid; Methods; Mice; Microfluorometry, Flow; Molecular Interaction; Morphology; Mother Cells; Muco Sanigen; Mucocedyl; Mucolator; Mucolyticum; Mucomyst; Mucosolvin; Mucret; Murine; Mus; N-Acetyl Cysteine; N-Acetyl-L-cysteine; N-Acetylcysteine; N-acetyl-3-mercaptoalanine; N-terminal; NAC; NAC Zambon; NH2-terminal; Neo-Fluimucil; NeuAcalpha1-3Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta1-1Cer; Nuclear; Opsonic Glycoprotein; Opsonic alpha(2)SB Glycoprotein; Optipect Hustengetr??nk; PEG; PEG-DA; Parvolex; Phase; Plastics; Polyethylene Glycols; Polyethylene Oxide; Polyethyleneoxide; Polyoxyethylenes; Process; Produpharm Lappe Brand of Acetylcysteine; Progenitor Cells; Proteins; Reaction; Recovery; Research Personnel; Researchers; Respaire; Roberts Brand of Acetylcysteine; SSEA-4; Serum; Serum Spreading Factor; Stem cells; Sulfhydryl Compounds; Surface; System; System, LOINC Axis 4; Testing; Thiemann Brand of Acetylcysteine; Thiols; Tissue Growth; Tixair; Type IV (Basement Membrane) Collagen; UPSA Brand of Acetylcysteine; Undifferentiated; VTN; Vitronectin; Zambon Brand of Acetylcysteine; Zyma Brand of Acetylcysteine; alpha 2-Surface Binding Glycoprotein; base; cell growth; cell type; cross-link; crosslink; experiment; experimental research; experimental study; falls; flow cytophotometry; gene product; hESC; human ES cell; human ESC; human disease; human embryonic stem cell; immunocytochemistry; induced pluripotent stem cell; matrigel; ontogeny; poly(ethylene glycol)diacrylate; poly(ethyleneglycol) diacrylate; polyethyleneglycol diacrylate; public health relevance; research study; self-renewal; stage-specific embryonic antigen 4; stemness; sulfhydryl group; synthetic peptide; tissue culture

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----